DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Valcyte (Valganciclovir Hydrochloride) - Current Clinical Trials


Valcyte Related Clinical Trials

IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients [Completed]

Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition [Completed]

Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition [Completed]

Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation [Terminated]

Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients [Completed]

Valganciclovir in Congenital CMV Infants [Completed]

Valganciclovir to Reduce T Cell Activation in HIV Infection [Completed]

ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation [Recruiting]

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections [Completed]

Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection [Active, not recruiting]

Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease [Withdrawn]

Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients. [Completed]

Suppression of Oral HHV8 Shedding With Valganciclovir [Completed]

A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients [Completed]

Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV) [Active, not recruiting]

Congenital CMV and Hearing Loss in Children up to 4 Years of Age: Treating With Valganciclovir Therapy [Recruiting]

Efficacy and Safety of ValcyteŽ as an Add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection [Active, not recruiting]

WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (ValcyteŽ) at a Dose of 900mg in Kidney Transplant Recipients [Terminated]

Oral Valganciclovir Versus Valacyclovir [Completed]

Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation [Completed]

Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant [Terminated]

Congenital Cytomegalovirus: Efficacy of Antiviral Treatment [Recruiting]

Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial [Terminated]

VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients [Completed]

A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients [Completed]

A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation [Active, not recruiting]

Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients [Completed]

Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients [Completed]

Pharmacokinetics of Mmf and Valganciclovir [Recruiting]

Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT) [Completed]

Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma [Completed]

A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age [Completed]

Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection [Active, not recruiting]

A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis. [Completed]

MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus [Terminated]

Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders [Terminated]

Study of Prophylactic Vs Preemptive Valganciclovir [Completed]

An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients [Completed]

CerticanŽ (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients [Recruiting]

Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients [Completed]

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies [Terminated]

Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients [Recruiting]

TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant [Completed]

Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation [Completed]

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer [Active, not recruiting]

Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy [Recruiting]

A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS [Completed]

The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection. [Completed]

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV [Completed]

SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipients [Not yet recruiting]

Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients [Not yet recruiting]

Cytomegalovirus Control in Critical Care [Completed]

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation [Completed]

An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls [Recruiting]

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant [Completed]

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity [Recruiting]

Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV) [Completed]

Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure [Recruiting]

Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients [Completed]

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma [Completed]

Antiviral Treatment of Chronic Lymphocytic Leukemia [Completed]

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure [No longer available]

A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes [Completed]

Tocilizumab for KSHV-Associated Multicentric Castleman Disease [Recruiting]

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation [Recruiting]

Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center [Not yet recruiting]

Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients [Recruiting]

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults [Completed]

Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients [Completed]

Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients [Completed]

Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients [Completed]

Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients [Completed]

Alternate Donor Study of Pre-Emptive Cellular Therapy [Completed]

Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study [Completed]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017